Replimune Group, Inc. 4

Baker Bros.-affiliated funds 667, L.P. and Baker Brothers Life Sciences LP purchased 2,736,340 Replimune Group, Inc. 2026 $0.0001 prefunded warrants for about $33 million in an underwritten offering on August 11, 2026.

On August 11, 2026, Baker Bros. Advisors LP and related Baker entities, acting as directors by deputization of Replimune Group, Inc., caused their affiliated funds 667, L.P. and Baker Brothers Life Sciences LP to purchase an aggregate 2,736,340 of Replimune’s 2026 $0.0001 Prefunded Warrants in an underwritten public offering at $12.0599 per warrant. These prefunded warrants are immediately exercisable into common stock on a 1-for-1 basis at a de minimis $0.0001 exercise price, subject to a 4.99% beneficial ownership cap (adjustable up to 19.99% with 61 days’ notice). The total cash outlay for the Baker complex was approximately $33.0 million, representing a sizable insider capital commitment into a quasi-equity instrument economically equivalent to common stock, while preserving flexibility around ownership thresholds under Section 13(d) and Section 16.

Filing Facts

CIK

1737953

Ticker

REPL

Form

4

Source Type

fda

Accession

0001193125-26-345144

Alert Tier

8